- 2 hrs ago Actress Kriti Sanon Is A Dream In Pink Ethnic Wear - See Pics!
- 4 hrs ago Monkeypox In Children: Symptoms To Watch Out For And More Details
- 7 hrs ago Monkeypox Vs Coronavirus: How The Two Infections Differ From Each Other
- 9 hrs ago Jagannath Rath Yatra 2022: Greetings, Wishes, Quotes, SMS, Messages, And Images
- Sports Khelo India Youth Games: Daughter of a plumber, star sprinter Avantika eyes gold in Haryana
- Finance Emkay Global Gives A Buy Call To This Maharatna Stock For A Potential Gain Of 27.3%
- Automobiles Top 10 Best Selling 6-seater/7-seater UVs In April 2022
- News Monkeypox spreads only through monkeys? 6 myths about the infection busted
- Movies MIFF 2022: 102 Documentary, Short Fiction And Animation Films Competing For Golden Conch & Silver Conch Awards
- Education UPSC Prelims Exam On June 5, Important Topics To Be Revised Before CSE 2022
- Technology How To Mark Parking Spot In Google Maps
- Travel June 2022: Indian Festivals And Events Guide
The Omicron variant of coronavirus may evade several, but not all, monoclonal antibodies used clinically to prevent patients from developing severe COVID-19, according to a laboratory study.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens such as viruses.
Several past studies have shown that such antibodies are unsuccessful in neutralising Omicron.
The team led by researchers at Washington University, US, tested five antibody combinations, including those discovered at Vanderbilt University Medical Centre (VUMC) in the US.
The study, recently published in the journal Nature Medicine, found that antibodies, including those in clinical use by biopharmaceutical companies Celltrion, Regeneron and Eli Lilly, completely lost the ability to neutralise Omicron in cell culture.
The antibodies developed at VUMC had a reduced neutralising ability, while as an antibody developed by Vir Biotechnology, US, was minimally affected, the researchers found.
"Omicron escapes recognition by several of the monoclonal antibodies that are being used for therapy," said James Crowe director of the Vanderbilt Vaccine Center, whose team discovered the monoclonal antibodies at VUMC which were later optimised by AstraZeneca into an antibody combination called Evusheld.
"The precursor antibody of Vir Biotechnology's sotrovimab, and the prophylaxis antibodies in Evusheld retain substantial though reduced activity," said Crowe, coauthor of the research paper.
Although these data suggest that some monoclonal antibodies in clinical use might retain the benefit, more experiments are needed to support this conclusion and inform clinical decisions, the authors noted.
The loss of neutralising ability in Omicron is due to the more than 30 mutations in its "spike" protein, the antibody target on the surface of the virus which helps it to enter and infect cells.
The loss of inhibitory activity in the study is consistent with the observation that antibody responses generated after vaccination or natural infection also lose substantial inhibitory activity against Omicron, the researchers said.
That finding may explain in part the rise in symptomatic infections caused by the Omicron variant in people who have previously been vaccinated, they said.
The study "is good news, since we still have a least one antibody-drug we can use for each of the indications, prevention or therapy," Crowe added.
The continued identification and use of broadly and potently neutralising monoclonal antibodies that target the most highly conserved and least likely to mutate portions of the spike protein are needed to protect against Omicron and future variants, the researchers added.
- wellnessEven Vaccinated People Can Develop Long Covid, Study Finds
- wellnessHypertension Most Common Co-Morbidity: Delhi Hospital Study On Covid-19 Patients
- womenWHO Honours 1 Million ASHA Women For COVID-Care Role
- wellnessAir Pollution Linked With More Severe COVID-19: Study
- wellnessOmicron Subvariants BA.4 And BA.5 In India: What You Need To Know
- wellnessHaven't Had Covid-19 Yet? It Could Be More Than Just Luck
- disorders cureWhat Is Geographic Tongue? Is It Related To COVID? Read About The Causes And Symptoms
- wellnessWhy People With Lung Disorder Face Risk Of Severe Covid-19 Found
- wellnessIndia's First mRNA Vaccine Against COVID: 90% Effective; Can Be Used For Malaria, Dengue Etc.
- wellnessOestrogen Treatment Linked With Reduced Covid Mortality: Study
- wellnessTrained Sniffer Dogs May Accurately Detect COVID Infected Airport Passengers: Study
- wellnessBiological E Ltd Reduces Price Of Its Covid-19 Vaccine Corbevax To Rs 250 Per Dose